- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Nanobac Pharmaceuticals, Inc. Launches International Team to Test Promising New Therapy for Stone Forming Diseases
Tampa, FL | Posted on March 30, 2006
Nanobac Pharmaceuticals, Inc. (NNBP) ("Nanobac" or "the Company") announced today new initiatives focusing on diagnostic and therapeutic solutions for stone forming diseases. Capitalizing on its intellectual property estate, recent discoveries and pending intellectual property, the Company will utilize a team of internationally recognized medical and drug development experts to test a promising drug combination and diagnostics that might improve patient outcomes in painful stone-forming diseases such as prostatitis, gallstones and kidney stones where no effective treatment is available.
The Company has worked with researchers from Cleveland Clinic and Mayo Clinic, has ongoing research at NASA and the University of California San Francisco, and is adding research teams from Sweden and Finland to test the discovery of a drug combination found to inhibit calcifying nanoparticles associated with stone forming diseases. Work on diagnostic solutions has already begun or been concluded in some instances.
In support of its new initiatives, Nanobac announced today that Dr. Benedict S. Maniscalco, a cardiologist with extensive experience treating calcification-related conditions, has been appointed head of research initiatives and Co-Chairman of the Board.
Dr. Maniscalco has been repeatedly voted by physician peers as one of the "Best Doctors in America." He founded St. Joseph's Hospital Heart Institute in Tampa and is head of the internationally recognized Heartbeat International which donates life saving pacemakers in lesser developed countries. He was principle investigator in a study on a novel therapy for atherosclerosis.
Dr. Hector Gomez, M.D. PhD, will be special advisor to Dr. Maniscalco on drug and diagnostics development. He is a former Merck and Novartis research executive with extensive experience bringing therapies to market in FDA and European regulatory environments, and in supervising clinical trial work in other countries. He has successfully brought biotech companies public and currently heads an R&D company near Tampa.
"Dr. Maniscalco's and Dr. Gomez' combination of clinical treatment, medical innovation and drug development experience adds a needed dimension to the quest for an effective treatment for stone forming diseases," said John Stanton, CEO and Chairman. "This will enhance our focus on proving the effectiveness of drug combinations in ways that will meet new FDA drug and diagnostics standards."
"This initiative has the added advantage of being tied to diagnostics to measure patient improvements before other methods can," Dr. Maniscalco said. "That capability comes from measuring the level of calcifying nanoparticles in blood."
The same calcified particles found in stone-forming diseases are found in atherosclerosis, but until now have been hard to diagnose or treat. Dr. Maniscalco has extensive experience treating coronary calcification.
The Company also announced that, effective immediately, Nanobac is narrowing its near-term focus to improving patient outcomes with drug combinations for such diseases, and will discontinue the sale of supplements and nutraceuticals.
The initiative follows the filing of multiple patent applications with regard to stone forming diagnostics and therapies and the publishing of an observational study at Cleveland Clinic showing that prostatitis patients improve with our experimental drug combination, and that no serious adverse reactions were encountered. Another combination therapy patented by Nanobac has shown promising results in vitro. The team will focus on that new combination.
"This is an exciting new start for patients with stone forming diseases, and for Nanobac," Dr. Maniscalco concluded, "The focus is extremely sharp. We are attacking stone forming diseases with a potentially effective and uniquely measurable drug combination whose effects could be shown in the early phase using new diagnostics."
About Nanobac Pharmaceuticals, Inc.:
Nanobac Pharmaceuticals, Inc. is a broad-based life science company dedicated to the discovery and developments of products and services to improve people's health through the detection and treatment of Calcifying Nano-Particles, otherwise known as "nanobacteria". The Company's pioneering research is establishing the pathogenic role of nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease.
Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and reagents for the detection of Calcifying Nano-Particles. IVD products include the NANOCAPTURE(TM) and NANO-SERO(TM) ELISA assays and the Nano-Vision(TM) line of antibodies and reagents. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials. Nanobac's Drug Discovery and Development efforts are focused on developing new and existing compounds that effectively inhibit, destroy or neutralize CNPs.
Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida.
Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.
For more information, please click here.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016
Leti IEDM 2016 Paper Clarifies Correlation between Endurance, Window Margin and Retention in RRAM for First Time: Paper Presented at IEDM 2016 Offers Ways to Reconcile High-cycling Requirements and Instability at High Temperatures in Resistive RAM December 6th, 2016
Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016